Kadmon Holdings (NYSE: KDMN) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Kadmon Holdings to related businesses based on the strength of its earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
This table compares Kadmon Holdings and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kadmon Holdings Competitors||-13,597.63%||-103.31%||-25.61%|
27.5% of Kadmon Holdings shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 8.4% of Kadmon Holdings shares are held by insiders. Comparatively, 15.5% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Kadmon Holdings and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Kadmon Holdings||$26.06 million||-$208.75 million||-2.05|
|Kadmon Holdings Competitors||$563.95 million||$96.15 million||51.40|
Kadmon Holdings’ rivals have higher revenue and earnings than Kadmon Holdings. Kadmon Holdings is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Kadmon Holdings has a beta of 2.74, meaning that its share price is 174% more volatile than the S&P 500. Comparatively, Kadmon Holdings’ rivals have a beta of 1.17, meaning that their average share price is 17% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Kadmon Holdings and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kadmon Holdings Competitors||128||794||1733||59||2.63|
Kadmon Holdings presently has a consensus price target of $9.75, suggesting a potential upside of 171.59%. As a group, “Biopharmaceuticals” companies have a potential upside of 15.08%. Given Kadmon Holdings’ higher probable upside, equities research analysts plainly believe Kadmon Holdings is more favorable than its rivals.
Kadmon Holdings rivals beat Kadmon Holdings on 8 of the 12 factors compared.
Kadmon Holdings Company Profile
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.